Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721135 | 0.86 | CALM1 (0.44) | HTR2ACALM1BCL2BCL2L1DRD2 | |
| SCHEMBL687988 | 0.83 | LMNA (0.40) | TP53HTR2ACALM1BCL2BCL2L1 | |
| SCHEMBL28763236 | 0.81 | BCL2 (0.42) | HTR2ACALM1BCL2BCL2L1L3MBTL1 | |
| SCHEMBL7432943 | 0.81 | L3MBTL1 (0.40) | HTR2ACALM1BCL2BCL2L1L3MBTL1 | |
| SCHEMBL64051 | 0.80 | GABRA1 (0.41) | L3MBTL1 | |
| SCHEMBL7687255 | 0.77 | HTR2A (0.37) | HTR2ACALM1BCL2BCL2L1CYP1A2 | |
| SCHEMBL7453243 | 0.77 | CALM1 (0.42) | TP53HTR2ACALM1BCL2BCL2L1 | |
| SCHEMBL2410994 | 0.77 | HTR2A (0.42) | TP53HTR2ACALM1BCL2BCL2L1 | |
| SCHEMBL5150284 | 0.76 | HTT (0.41) | TP53DRD2TSHR | |
| SCHEMBL16953556 | 0.75 | GABRA1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | claimed |
| EP-1252156-B1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UCL BUSINESS PLC (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| WO-2008104756-A1 | UREA DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| WO-2005113525-A1 | N, N’-SUBSTITUTED-1,3-DIAMINO-2-OXOPROPANE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND USE | GLAXO GROUP LIMITED (GB) | 2005-12-01 | — | — | WO | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
| EP-1252156-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | University College London (GB) | 2002-10-30 | — | — | EP | disclosed |
| EP-1140900-A4 | PYRAZOLE COMPOUNDS AND USES THEREOF | PPD DISCOVERY INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1140900-A2 | PYRAZOLE COMPOUNDS AND USES THEREOF | PPD DISCOVERY, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001057024-A1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000039083-A2 | PYRAZOLE COMPOUNDS AND USES THEREOF | PPD DISCOVERY, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0058740-B1 | IMPROVED POLYESTER MOLDING COMPOSITIONS AND MOLDED ARTICLES PRODUCED THEREFROM | UNION CARBIDE CORPORATION (US) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | TP53 4611/4885HTR2A 3268/4885CALM1 952/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | TP53 4608/4885HTR2A 3287/4885CALM1 1057/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | TP53 3868/4885HTR2A 48/4885CALM1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.